Skip to Main Content

Paper Details

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Neuro Oncol
15
2023
antitumor, cancer, irinotecan, lomustine, patient, patients, recurrent glioblastoma, temozolomide
Author NameAffiliation
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingson
Benjamin M Ellingson
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program
Benjamin M Ellingson
Benjamin M Ellingson
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School
Michael A VogelbaumMoffitt Cancer Center
John F de GrootUniversity of California San Francisco
Michael WellerUniversity Hospital and University of Zurich
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 18

Datasets

Release 1.2